Dr. Adam Olson
Claim this profileUPMC-Shadyside Hospital
Studies Prostate Cancer
Studies Prostate Adenocarcinoma
15 reported clinical trials
52 drugs studied
Area of expertise
1Prostate Cancer
White blood cell count (WBC)
ALT
Bone metastases
2Prostate Adenocarcinoma
Stage IV
Affiliated Hospitals
Clinical Trials Adam Olson is currently running
Stem Cell Transplant
for Scleroderma
The purpose of this study is to determine whether a regimen of high-dose immunoablative therapy will demonstrate safety that is consistent or improved with other published regimens in SSc patients, while maintaining a treatment effect.
Recruiting1 award Phase 215 criteria
Stereotactic Radiation + Immunotherapy
for Kidney Cancer
This phase II trial tests whether the addition of radiation to the primary tumor, typically given with stereotactic ablative radiation therapy (SABR), in combination with standard of care immunotherapy improves outcomes in patients with renal cell cancer that is not recommended for surgery and has spread to other places in the body (metastatic). Radiation therapy uses high energy photons to kill tumor cells and shrink tumors. Stereotactic body radiation therapy uses special equipment to position a patient and deliver radiation to tumors with high precision. This method may kill tumor cells with fewer doses of radiation over a shorter period and cause less damage to normal tissue. Immunotherapy with monoclonal antibodies, such as nivolumab, ipilimumab, avelumab, and pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Axitinib, cabozantinib, and lenvatinib are in a class of medications called antiangiogenic agents. They work by stopping the formation of blood vessels that bring oxygen and nutrients to tumor. This may slow the growth and spread of tumor. Giving SABR in combination with standard of care immunotherapy may help shrink or stabilize the cancer in patients with renal cell cancer.
Recruiting1 award Phase 221 criteria
More about Adam Olson
Clinical Trial Related6 years of experience running clinical trials · Led 15 trials as a Principal Investigator · 9 Active Clinical TrialsTreatments Adam Olson has experience with
- Apalutamide
- Bicalutamide
- Radiation Therapy
- Cabozantinib
- Histrelin
- Leuprolide
Breakdown of trials Adam Olson has run
Prostate Cancer
Prostate Adenocarcinoma
Cancer
Renal Cell Carcinoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Adam Olson specialize in?
Adam Olson focuses on Prostate Cancer and Prostate Adenocarcinoma. In particular, much of their work with Prostate Cancer has involved White blood cell count (WBC) patients, or patients who are ALT.
Is Adam Olson currently recruiting for clinical trials?
Yes, Adam Olson is currently recruiting for 9 clinical trials in Pittsburgh Pennsylvania. If you're interested in participating, you should apply.
Are there any treatments that Adam Olson has studied deeply?
Yes, Adam Olson has studied treatments such as Apalutamide, Bicalutamide, Radiation Therapy.
What is the best way to schedule an appointment with Adam Olson?
Apply for one of the trials that Adam Olson is conducting.
What is the office address of Adam Olson?
The office of Adam Olson is located at: UPMC-Shadyside Hospital, Pittsburgh, Pennsylvania 15232 United States. This is the address for their practice at the UPMC-Shadyside Hospital.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.